Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
Back to alerts
THEMISMEDNSEThemis Medicare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 13 Nov, 2025 · 13:24 IST

Q2 FY26 results: Revenue declines sharply, swings to loss

Revenue declinedNet loss reportedExceptional itemNegative operating cash flowResults View source PDFExplain this filing

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-4.1%Reaction day
₹123.00
prior close
₹119.67
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.0% vs market
Pharmaceuticals peers, median of 157sector-0.0%-4.0% vs sector

On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 4.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.5
10m
-0.1
15m
-0.2
30m
-0.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-4.1-0.1-4.0-0.0-4.0
Next day
-4.9-0.2-4.7-0.4-4.4
2d
-5.7+0.4-6.1-0.3-5.3
3d
-7.2-0.4-6.8-1.0-6.2
4d
-9.0-0.6-8.4-1.3-7.7
5d
-8.7-0.9-7.8-1.5-7.2
1w
-15.2-3.0-12.2-3.2-12.1
15d
-13.4-3.9-9.6-3.4-10.0
1m
-14.6-4.8-9.8-4.0-10.6
2m
-21.3-7.8-13.5-6.6-14.7
3m
-25.2-7.2-18.0-8.5-16.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Themis Medicare reported Q2 FY26 standalone revenue of Rs 77.99 crores, down sharply from Rs 117.01 crores YoY. H1 FY26 loss after tax was Rs 20.73 crores versus profit of Rs 28.59 crores last year. EPS stood at minus Rs 2.25 for the half year. The company booked an exceptional item of Rs 1.29 crores on UK subsidiary write-off.

Likely market impact

Sharp revenue decline and swing to loss versus profit a year ago signals weak performance; UK subsidiary write-off booked as exceptional item adds pressure.